Invion

Invion Piotroski F-Score

The Piotroski F-Score of Invion (IVX.AX) as of Oct 22, 2026 is 4. In the previous year, Piotroski F-Score was 2.00 — a change of 100.00% (higher).

Piotroski F-Score

4

YoY

100.00%

Last updated:

Piotroski F-Score of Invion is 2026 4 . Piotroski F-Score of Invion was 2025 2.00 . It decreases by 100.00% higher compared to the previous year.

The Invion Piotroski F-Score history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Piotroski F-Score
Date
Piotroski F-Score
Jan 1, 2019
3.00 AUD
Jan 1, 2020
5.00 AUD
Jan 1, 2021
3.00 AUD
Jan 1, 2022
4.00 AUD
Jan 1, 2023
3.00 AUD
Jan 1, 2024
3.00 AUD
Jan 1, 2025
2.00 AUD
Jan 1, 2026
4.00 AUD
The Invion Piotroski F-Score history
YEARPiotroski F-ScoreYoY
4+100.00%
2-33.33%
30.00%
3-25.00%
4+33.33%
3-40.00%
5+66.67%
3-50.00%
6+200.00%
2-60.00%
5+150.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Piotroski F-Score of Invion is 4 in 2026.

On Eulerpool you can find the complete historical development of Piotroski F-Score Invion since 2006 – with annual values, charts, and detailed analysis.

The Piotroski F-Score rates a company from 0-9 based on profitability, leverage, liquidity, and operating efficiency. Scores of 8-9 indicate strong fundamentals.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Invion

All Key Metrics — Invion